Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Extends program benefits to oncology labs and fast-tracks access to comprehensive molecular profiling on the Genexus System.
July 28, 2020
By: Contract Pharma
Contract Pharma Staff
Thermo Fisher Scientific has expanded its GlobalAccess Sequencing Program to include laboratories working in oncology. Originally introduced to accelerate multi-institutional-led studies focused on SARS-CoV-2, the expanded program now provides support to labs facing significant constraints as a result of the global pandemic by offering faster access to comprehensive, single-day molecular profiling of tumor tissue on Thermo Fisher’s Ion Torrent Genexus System.
Under the GlobalAccess Sequencing Program, Thermo Fisher will subsidize a limited number of Genexus Systems* for a short time to serve its customers during the global pandemic. The program, which is open to pathology laboratories that currently run or wish to begin sequencing samples with oncology assays, is available immediately and will continue through the end of this year.
The Genexus System was launched in November 2019 with the Oncomine Precision Assay*, which most recently received Breakthrough Device Designation by the U.S. FDA to identify low-grade glioma (LGG) patients with isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations who may be eligible for vorasidenib (AG-881). The next-generation sequencing (NGS) solution features an automated specimen-to-report workflow that delivers results in a single day.
The system is designed to minimize user intervention and is conducive for maintaining social distancing requirements in a decentralized lab setting. It requires minimal amounts of tissue sample and can run small batches cost-effectively. Together, these features will enable hospitals to adopt NGS testing in-house and sets the stage for molecular pathologists to eventually analyze NGS information in parallel with first-line testing modalities, such as immunohistochemistry (IHC).
In May, Thermo Fisher announced the SARS-CoV-2 GlobalAccess program to accelerate efforts focused on mapping coronavirus transmission and epidemiological studies by research consortia and industry groups.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !